OC
CRSP icon

Oakworth Capital’s CRISPR Therapeutics CRSP Stock Holding History

Oakworth Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.9K Hold
646
– – ﹤0.01% 514
2026
Q1 		$30.7K Hold
646
– – ﹤0.01% 522
2025
Q4 		$33.9K Buy
+646
New +$38.7K ﹤0.01% 497

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return

Oakworth Capital's CRSP Position: Q2 2026 in Review

Oakworth Capital held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 646 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #514.

Oakworth Capital first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Oakworth Capital held 646 shares of CRISPR Therapeutics worth $35.9K as of Q2 2026.
  • Oakworth Capital left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Oakworth Capital's portfolio in Q2 2026, its #514 holding.
  • Oakworth Capital first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 189 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.